Zobrazeno 1 - 10
of 114
pro vyhledávání: '"David M. Ota"'
Autor:
Lee Trani, Judy C. Boughey, MJ Ellis, Vera J. Suman, Aman U. Buzdar, K. K. Hunt, Mark A. Watson, Malachi Griffith, Jasreet Hundal, Rebecca Aft, A. M. Leitch, Obi L. Griffith, Robert Lesurf, Funda Meric-Bernstam, Elaine R. Mardis, David M. Ota, Gary Unzeitig
Publikováno v:
Annals of Oncology. 28:1070-1077
Background HER2 (ERBB2) gene amplification and its corresponding overexpression are present in 15–30% of invasive breast cancers. While HER2-targeted agents are effective treatments, resistance remains a major cause of death. The American College o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::255ea748d2f370dd1f9ebe8cc46f9b84
https://doi.org/10.1093/annonc/mdx048
https://doi.org/10.1093/annonc/mdx048
Autor:
Kelly K. Hunt, Erika C. Crouch, Yu Tao, Rodrigo Franco Gonçalves, Lisa A. Carey, Timothy J. Pluard, Gary Unzeitig, Mitchell Dowsett, Marilyn Leitch, Pat Whitworth, Eric P. Winer, Chad J. Creighton, G. Thomas Budd, John A. Olson, David M. Ota, D. Craig Allred, Vera J. Suman, Katherine DeSchryver, Jingqin Luo, Jeremy Hoog, Cynthia X. Ma, Laura J. Esserman, Amy Brink, Mark A. Watson, Matthew J. Ellis, Michael Barnes, Paula Silverman, Zoneddy Dayao, Gildy Babiera, Souzan Sanati, J. Michael Guenther
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 35, iss 10
Journal of Clinical Oncology
Journal of Clinical Oncology
Purpose To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) –positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 to 4 weeks of neoadjuvant a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::674801577977c8c9dc9d96a7c7d503cf
https://escholarship.org/uc/item/5qb5216t
https://escholarship.org/uc/item/5qb5216t
Autor:
Mark A. Watson, Sandra McDonald, John D. Pfeifer, Jonathan M. Green, Elaine R. Mardis, David M. Ota
Publikováno v:
American Journal of Clinical Pathology. 138:31-41
As part of the molecular revolution sweeping medicine, comprehensive genomic studies are adding powerful dimensions to medical research. However, their power exposes new regulatory, strategic, and quality assurance challenges for biorepositories. A k
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fca674e1053c354a7a0392ce596164a6
https://doi.org/10.1309/ajcpxba69lnscvmh
https://doi.org/10.1309/ajcpxba69lnscvmh
Autor:
Li-Wei Chang, Karla V. Ballman, Sandra McDonald, Matthew J. Ellis, Chris Harris, Timothy J. Ley, Reece J. Goiffon, David Piwnica-Worms, Li Lin, Mark A. Watson, David J. Dooling, David M. Ota, William Schierding, Ken Chen, Gary Unzeitig, Feiyu Du, Ben Oberkfell, Ron Bose, P. Kelly Marcom, John W. Wallis, Jason D. Weber, Dong Shen, Sam Ng, Cyriac Kandoth, Charles Lu, J. M. Guenther, Vera J. Suman, Elaine R. Mardis, Tammi L. Vickery, Helen Piwnica-Worms, Laura J. Esserman, Jeremy Hoog, Robert J. Crowder, Lucinda Fulton, Yu Tao, Christopher A. Miller, Gildy Babiera, Joshua F. McMichael, Theodore C. Goldstein, Adnan Elhammali, Joshua M. Stuart, Richard K. Wilson, Brian A. Van Tine, Michael C. Wendl, Robert S. Fulton, Li Ding, Ryan Demeter, Jacqueline E. Snider, Julie A. Margenthaler, John A. Olson, Michelle Harrison, D. Craig Allred, Katherine DeSchryver, Jingqin Luo, Marilyn Leitch, Christopher G. Maher, Michael D. McLellan, Kelly K. Hunt, Daniel C. Koboldt
Publikováno v:
Nature
Summary To correlate the variable clinical features of estrogen receptor positive (ER+) breast cancer with somatic alterations, we studied pre-treatment tumour biopsies accrued from patients in a study of neoadjuvant aromatase inhibitor (AI) therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e662efd52198c84afc976af33f07d033
http://europepmc.org/articles/PMC3383766
http://europepmc.org/articles/PMC3383766
Autor:
Bettye Green, Dennis R. Holmes, Armin D. Weinberg, Erin M. Green, Wayne Frederick, Jane E. Méndez, Kathleen M. Diehl, Heidi Nelson, Venus Gines, David M. Ota, Arden M. Morris, Henry Mark Kuerer, Robert A. Beltran, Lisa A. Newman
Publikováno v:
Annals of Surgical Oncology. 18:3544-3550
The clinical trials mechanism of standardized treatment and follow-up for cancer patients with similar stages and patterns of disease is the most powerful approach available for evaluating the efficacy of novel therapies, and clinical trial participa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e8899075556054dff0aecddd5ad7ebc
https://doi.org/10.1245/s10434-011-1818-9
https://doi.org/10.1245/s10434-011-1818-9
Autor:
Cheryl T. Lee, Heidi Nelson, David M. Ota, Charles R. Thomas, Anthony Lucci, Andrew K. Stewart, Lina Patel Parekh, Lisa A. Newman, Robert A. Beltran, Bettye Green
Publikováno v:
Cancer. 106:188-195
BACKGROUND Disparities in cancer outcome among different subsets of the American population related to ethnic background have been well documented. Clinical trials represent the most powerful strategy for improving cancer treatments, but racial and e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fe892db61d45cc8b3064cf717ccbea2
https://doi.org/10.1002/cncr.21592
https://doi.org/10.1002/cncr.21592
Autor:
Richard Flanagan, Heidi Nelson, Michael D. Hellinger, Mehran Anvari, H Sam Wieand, Daniel J. Sargent, Robert W. Beart, Steven J. Stryker, Walter R. Peters, James W. Fleshman, David M. Ota
Publikováno v:
New England Journal of Medicine. 350:2050-2059
background Minimally invasive, laparoscopically assisted surgery was first considered in 1990 for patients undergoing colectomy for cancer. Concern that this approach would compromise survival by failing to achieve a proper oncologic resection or ade
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0418e12d4085ae120d232d7102013be9
https://doi.org/10.1056/nejmoa032651
https://doi.org/10.1056/nejmoa032651
Autor:
Parvaneh Rafiee, Henning R. Gockel, David G. Binion, Norbert Lügering, Hitoshi Ogawa, David M. Ota, Jan Heidemann, Wolfram Domschke, Mary F. Otterson, Michael B. Dwinell, Christian Maaser
Publikováno v:
Journal of Biological Chemistry. 278:8508-8515
Angiogenesis plays a critical role in metastasis and tumor growth. Human tumors, including colorectal adenocarcinoma, secrete angiogenic factors, inducing proliferation and chemotaxis of microvascular endothelial cells, eventually leading to tumor ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67c6ea2945740649161ed0cf27c6eb6b
https://doi.org/10.1074/jbc.m208231200
https://doi.org/10.1074/jbc.m208231200
Autor:
David M. Ota, K Lin
Publikováno v:
Swiss Surgery. 7:252-255
The primary treatment of resectable CRC is surgical resection. Postoperative adjuvant therapies are recommended when lymph node metastases are found (stage III). There is evidence that about 20% of node negative CRC cases (stage II) are understaged,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b813ee734979899d27fbe9c8dc84e0e
https://doi.org/10.1024/1023-9332.7.6.252
https://doi.org/10.1024/1023-9332.7.6.252
Autor:
Jose G. Guillem, Nicholas J. Petrelli, James W. Fleshman, Arthur M. Carlin, Jean Couture, David M. Ota, Daniel J. Sargent, Brent W. Miedema, Heidi Nelson
Publikováno v:
Scopus-Elsevier
Background Oncologic resection techniques affect outcome for colon cancer and rectal cancer, but standardized guidelines have not been adopted. The National Cancer Institute sponsored a panel of experts to systematically review current literature and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c49deb5c4cb222fc26732b21cc4533b7
https://doi.org/10.1093/jnci/93.8.583
https://doi.org/10.1093/jnci/93.8.583